

SystemONE referral by email for BLMK COVID Medicine Delivery Unit (CMDU)

Patients who are potentially eligible for antiviral treatment due to clinical vulnerability if they test positive for COVID-19 are now being advised to contact 111 or the GP surgery directly (the automatic referral portal "Webview" has been decommissioned).

If a patient contacts the surgery please follow the process below in S1 to refer them to the BLMK CMDU team for assessment and treatment if appropriate.

1. Click on the Communications (orange) arrow



2. Select local area:

3. The CMDU referral form is under "Community O" - "Others"

CLICK

COVID Medicine Delivery Unit (CMDU) REFERRAL FORM

Date of GP decision to refer: 05 Jun 2023 No. of pages sent:

PLEASE COMPLETE PROFORMA **WITHIN 24HRS** OF REQUEST AND EMAIL TO CDMU blmkicb.cmdu@nhs.net
The CMDU will assess the patient within 48 hours following receipt of referral.

PROFORMA CAN BE FOUND ON THE COMMUNITY REFERRALS TAB IN ARDENS ON SYSTMONE

This proforma is NOT for use for:
 Patients aged < 12 years, children <40kg, patients who are asymptomatic, patients showing signs of clinical improvement or patients requiring hospitalisation/new need for O₂

4. Complete the following information on the referral form:
- Date of positive test
 - Date of symptom onset
 - Current symptom status
 - High risk condition group
 - Reason for referral (page 2)

ELIGIBILITY:	
Date of positive LFT:	23/5/23
Date of symptom onset:	23/5/23
Patient remains symptomatic i.e. no evidence of clinical improvement:	not improving
Highest risk patient cohort group for ADULTS (18 years and older) (see Figure 1 for full details)	
<input type="checkbox"/> Down's syndrome and other genetic disorders <input type="checkbox"/> Solid cancer <input checked="" type="checkbox"/> Haematological diseases and recipients of haematological stem cell transplant (HSCT) <input type="checkbox"/> Renal disease <input type="checkbox"/> Liver diseases	<input type="checkbox"/> Solid organ transplant recipients <input type="checkbox"/> Immune-mediated inflammatory disorders <input type="checkbox"/> Respiratory <input type="checkbox"/> Immune deficiencies <input type="checkbox"/> HIV / AIDS <input type="checkbox"/> Neurological disorders
Highest risk patient cohort group for CHILDREN AND YOUNG PEOPLE (greater than 40kg, aged 12-17 years) (see Figure 2 for full details)	
<input type="checkbox"/> Those at substantial risk: Complex life-limiting neurodisability with recurrent respiratory infections or compromise.	<input type="checkbox"/> Those at significant risk if 2 or more of these risk factors are present: <input type="checkbox"/> Primary immunodeficiency <input type="checkbox"/> Secondary immunodeficiency <input type="checkbox"/> Immunosuppressive treatment <input type="checkbox"/> Other conditions

Reason for Referral:
 Chronic leukaemia (CLL) patient – COVID positive

5. Email the referral to blmkicb.cmdu@nhs.net



Consultations will be recorded on S1
 Oral antiviral medicine will be supplied via FP10